The Latest Cardiac and Vascular News
Company on track for sNDA submission to the FDA by year-end SPARTA, N.J., Nov. 08, 2019 (GLOBE NEWSWIRE) — PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company initially focused on developing its clinically validated and patent-protected PLxGuard™ delivery system to provide more effective and […]
SANTA CLARA, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months ended September 30, 2019. Recent Highlights Recognized revenue of $11.3 million […]
Results of EXTRACT-PE Trial presented at Vascular InterVentional Advances (VIVA) Annual Meeting LAS VEGAS – November 6, 2019 – Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today announced that the EXTRACT-PE trial successfully met the primary endpoints, demonstrating the safety and efficacy of the Indigo® […]
First Patient Enrolled in DISRUPT CAD IV Clinical Study for Treatment of Severely Calcified Coronary Arteries SANTA CLARA, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that the company […]
Third Quarter Highlights Global revenue up 2.9% versus prior year Sequential AFX system sales increase in the U.S. Operating cash burn of $4.0M for the quarter IRVINE, Calif.–(BUSINESS WIRE)–Endologix, Inc. (the “Company”) (NASDAQ: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced financial results for the […]
Reinforces prior study results demonstrating proportional dose response and that bioavailability of CaPre is not meaningfully affected by the fat content of a meal LAVAL, Québec, Nov. 07, 2019 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, […]
Vancouver, Nov. 07, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced the appointment of Bill Little […]
PRECISION-AF pivotal Phase 3 clinical trial initiation anticipated first quarter of 2020 Trial to examine atrial fibrillation in a heart failure population for which there are no FDA indicated drug therapies WESTMINSTER, Colo., Nov. 06, 2019 (GLOBE NEWSWIRE) — ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach […]
SAN FRANCISCO, Nov. 6, 2019 /PRNewswire/ — Recardio Inc., a life science company developing regenerative therapies for cardiovascular diseases, announced that it has rolled out its digital platform, CardioCare, throughout Europe to support its future clinical development programs in cardiovascular. Recardio’s Digital Platform CardioCare was awarded and presented at the ESC Conference 2018 and is now […]
– Company to Present Preliminary Data at American Heart Association Scientific Sessions – GERMANTOWN, Md., Nov. 7, 2019 /PRNewswire/ — Triple-Gene LLC, a clinical stage cardiovascular gene therapy company and majority owned subsidiary of Intrexon Corporation (NASDAQ: XON), today announced the completion of enrollment and dosing in its Phase 1 trial of INXN-4001, a […]
